Alendronate for Effective Treatment of Male Osteoporosis : An Insight

被引:0
作者
Al Lawati, Hanan [1 ]
Al Busaidi, Sara [2 ]
Al Rawahi, Thuraiya [3 ]
Al Lawati, Abdullah [4 ]
Kifah, Ahmed [5 ]
Das, Srijit [6 ]
机构
[1] Oman Coll Hlth Sci, Dept Pharmaceut, Pharm Program, Muscat, Oman
[2] Sultan Qaboos Univ, Muscat, Oman
[3] Royal Coll Surg Ireland Bahrain, Muharraq, Bahrain
[4] Sultan Qaboos Univ Hosp, Muscat, Oman
[5] Natl Univ, Sohar, Oman
[6] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Human & Clin Anat, Muscat, Oman
关键词
Alendronate; drug; osteoporosis; male; skeletal; bone; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE RISK; ZOLEDRONIC ACID; PARATHYROID-HORMONE; DOUBLE-BLIND; IN-VITRO; BISPHOSPHONATES; MEN; WOMEN; PREVALENCE;
D O I
10.2174/0113816128310838240820065324
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing phosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 141 条
[111]   Osteoporosis: Is the Prevalence Increasing in Saudi Arabia [J].
Sadat-Ali, Mir ;
AlZamami, Jana F. ;
AlNaimi, Shaykhah N. ;
Al-Noaimi, Dinah A. ;
AlDakheel, Dakheel A. ;
AlSayed, Hasan N. ;
Al-Turki, Haifa A. ;
AlOmran, Abdallah S. .
ANNALS OF AFRICAN MEDICINE, 2022, 21 (01) :54-57
[112]   Bone mineral density in healthy Tunisian women [J].
Sahli, Hela ;
Testouri, Nedia ;
Ben Chihaoui, Manel ;
Salah, Afef Hadj ;
Cheour, Elhem ;
Meddeb, Nihel ;
Zouari, Bechir ;
Sellami, Slaheddine .
MATURITAS, 2009, 63 (03) :227-232
[113]   A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss [J].
Santini, D. ;
Vincenzi, B. ;
Caraglia, M. ;
Tonini, G. .
ANNALS OF ONCOLOGY, 2007, 18 (01) :201-U5
[114]  
Sarafrazi N., 2021, Osteoporosis or Low Bone Mass in Older Adults: United States, 2017-2018, DOI [DOI 10.15620/CDC:103477, 10.15620/cdc:103477]
[115]   BISPHOSPHONATE ACTION - ALENDRONATE LOCALIZATION IN RAT BONE AND EFFECTS ON OSTEOCLAST ULTRASTRUCTURE [J].
SATO, M ;
GRASSER, W ;
ENDO, N ;
AKINS, R ;
SIMMONS, H ;
THOMPSON, DD ;
GOLUB, E ;
RODAN, GA .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (06) :2095-2105
[116]   Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women [J].
Sawka, AM ;
Papaioannou, A ;
Adachi, JD ;
Gafni, A ;
Hanley, DA ;
Thabane, L .
BMC MUSCULOSKELETAL DISORDERS, 2005, 6 (1)
[117]   Hypocalcemia associated with alendronate [J].
Schussheim, DH ;
Jacobs, TP ;
Silverberg, SJ .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (04) :329-329
[118]  
Scrimshaw B., 2012, GUIDANCE STOPPING AL
[119]   Bisphosphonates Use in Children [J].
Sebestyen, Judith F. ;
Srivastava, Tarak ;
Alon, Uri S. .
CLINICAL PEDIATRICS, 2012, 51 (11) :1011-1024
[120]  
Sewerynek E, 2011, ENDOKRYNOL POL, V62, P51